Revenue was sharply higher at Genmab A/S in the third quarter and the first nine months of 2014 owing to the clinical progress of the company’s monoclonal antibody daratumumab which is being investigated for multiple myeloma. ---Subscribe to MedNous to access this article--- Company News
